Results 151 to 160 of about 1,686,994 (258)

Evaluation of Etiological Factors in Patients with Chronic Urticaria

, 2015
In the last few decades, increasing understanding of the pathomechanisms involved in chronic urticaria has highlighted the heterogeneity of different subtypes, and chronic urticaria is now classified as chronic spontaneous urticaria and inducible ...
Gul, Ali Irfan, Utas, Serap, Ozyurt, Kemal, ÇÖLGEÇEN, EMİNE   +3 more
core  

Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases

Allergy, EarlyView.
ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz, Salvador Iborra, Carlos Blanco, Ruperto González‐Pérez, Emilio Nuñez‐Borque, Can Zeyneloglu, Huseyn Babayev, Ozlem Göksel, Tuncay Göksel, Musa Khaitov, Dmitry Kudlay, Yadong Gao, Mustafa Sevim, Marie‐Charlotte Brüggen, Oral Alpan, Ming Wang, Luo Zhang, María J. Torres, Mohamed Shamji, Mübeccel Akdis, Kari C. Nadeau, Ismail Ogulur, Cezmi A. Akdis   +22 more
wiley   +1 more source

Life-Threatening Eosinophilic Granulomatosis With Polyangiitis During Omalizumab Therapy for Chronic Urticaria: Missed Diagnosis, Induction, or Unmasking? [PDF]

Cureus
Zymaris P, Georgopoulou A, Tzioutzia A, Zacharias A, Margaritopoulos G, Sourla E, Boutou A, Pitsiou G.   +7 more
europepmc   +1 more source

Real‐World Outcomes of Omalizumab for Chronic Spontaneous Urticaria in a New Zealand Regional Dermatology Service

Australasian Journal of Dermatology, EarlyView.
Jeffrey Lee, Karen Koch
wiley   +1 more source

Efficacy and Safety of Abatacept Versus Placebo During Peanut Oral Immunotherapy for Adults With Severe Peanut Allergy

Allergy, EarlyView.
In this Phase 2a trial, severely peanut‐allergic participants were randomized to abatacept versus placebo with peanut oral immunotherapy (OIT) for 24 weeks, followed by 12 weeks of OIT alone. No significant difference was observed for the primary efficacy outcome (the relative change from baseline in peanut‐specific/total IgE ratio at 24 weeks), but ...
Marie‐Lee Simard, Camille Braun, Éloise Antony, Émilie Roy, Marie‐Ève Gingras, François Graham, Anne Des Roches, Louis Paradis, Kathryn Samaan, Florence Gingras‐Lessard, Roxane Labrosse, Thomas Eiwegger, Philippe Bégin   +12 more
wiley   +1 more source

Treatment-resistant chronic urticaria associated with papillary thyroid carcinoma: a case report. [PDF]

J Med Case Rep
Al Farsi M, Al Kiyumi MH.
europepmc   +1 more source

Safety and Clinical Outcomes of High‐ Versus Low‐Dose Oral Peanut Immunotherapy in Polish Children With Peanut Allergy

Acta Paediatrica, EarlyView.
ABSTRACT Aim To compare safety and clinical outcomes of two different oral immunotherapy (OIT) maintenance doses (150 mg vs. 300 mg) of peanut protein in children with peanut allergy. Methods This prospective study enrolled 44 children aged 4–17 years with confirmed peanut allergy.
Klementyna Łyżwa, Magdalena Chojnowska‐Wójtowicz, Wioletta Zagórska, Marek Kulus, Katarzyna Grzela   +4 more
wiley   +1 more source

Chronic urticaria: diagnostic workup and treatment

, 2007
Tedeschi A, GIROLOMONI, Giampiero, Asero R, the AAITO Committee for Chronic Urticaria, Pruritus G.u.i.d.e.l.i.n.e.s. AAITO Position paper   +4 more
core   +1 more source

Second-generation H1 antihistamines for the treatment of chronic urticaria: a network meta-analysis. [PDF]

Front Med (Lausanne)
Li Z, Zhang J, Zheng Y, Zhang M, Du W, Zhang Y, Gao X, Zhu Q, Qi J, Zhao Z, Liu L.   +10 more
europepmc   +1 more source

Factors Associated With Omalizumab Response in Chronic Spontaneous Urticaria: Are There Age‐Related Differences?

Acta Paediatrica, EarlyView.
ABSTRACT Aim This study aimed to explore clinical and laboratory markers of omalizumab response in paediatric and adult chronic spontaneous urticaria (CSU) patients. Methods The study included 32 children and 67 adults with CSU receiving omalizumab, and 29 paediatric and 30 adult healthy controls; associations with treatment response were evaluated ...
Güler Yıldırım Nalbant, Raif Coşkun, Nilay Çalışkan, Merve Karaca Şahin, Aslı Berivan Topçak, Muhammed Fatih Erbay, Çağla Öztürk Turan, Hilal Güngör, Hamit Boloğur, Hasan Tunç Şarman, Şule Papağan, Ömer Yılmaz Ulutaş, Şefika İlknur Kökçü Karadağ, Özlem Terzi, Deniz Özçeker   +14 more
wiley   +1 more source